Trovagene, Boreal Genomics Collaborate
News Dec 02, 2016
Trovagene Inc has announced that it has entered into a long-term Supply and Distribution Agreement with Boreal Genomics, merging their respective technologies to co-develop urine and blood ctDNA assay kits. Through this partnership, the companies intend to address an unmet need in the liquid biopsy testing market by providing a simple, routine and low-cost urine and blood ctDNA assay for next generation sequencing (NGS) platforms run by laboratories of Research Institutions, Cancer Centers, and service facilities around the world.
Trovagene and Boreal have each contributed proprietary technology and methods to enhance ctDNA detection capabilities from urine and blood to develop a series of cancer-specific multigene panels planned for launch in 2017. Initially, the panels will be designed to cover National Comprehensive Cancer Network® (NCCN) listed clinically actionable mutations with industry-leading sensitivity for which there are targeted therapies or treatment options available. The partnership’s goal is to address a gap between single-gene PCR assays that can be limited by sample availability and expensive, broad, multi-gene panels hindered by low clinical sensitivity for mutation detection.
The companies intend to develop additional panels throughout the partnership, and Trovagene plans to globally distribute the assay kits for use on the Boreal OnTarget™ system in blood and exclusively in urine. Trovagene’s initial research-use-only proprietary kits will include a urine collection kit, a urine extraction kit and a mutation enrichment kit, along with the Boreal OnTarget™ system.
“We are excited to partner with Boreal to be able to reach oncology professionals and their patients on a global basis through the distribution of our kits and systems,” said Bill Welch, Chief Executive Office of Trovagene. “Our commitment continues to focus on democratizing cancer care by harnessing urine and changing the landscape of the liquid biopsy market.”
“We’re thrilled to be able to partner with Trovagene to build these exciting technologies using our OnTarget™ platform,” said Andre Marziali, PhD, President and Chief Scientific Officer of Boreal Genomics. “Trovagene’s unique expertise in assay design for applications in urine, coupled with Boreal’s unique ctDNA enrichment technology, have created an immensely powerful tool for translational research, diagnostics and future early detection of disease.”
Features of the partnership include:
• Trovagene commits upfront and milestone payments totaling one million dollars
• Trovagene has global distribution and sub-distribution rights in blood and exclusively in urine for at least ten years
• Trovagene and Boreal will work together to have the kits and systems manufactured in a cGMP facility, and to take them through FDA, CE Mark, CFDA and other regulatory approval pathways
Source: Story from Boreal Genomics. Please note: The content above may have been edited to ensure it is in keeping with Technology Networks' style and length guidelines.
Anti-malaria drugs known as chloroquines have been repurposed to treat cancer for decades, but until now no one knew exactly what the chloroquines were targeting when they attack a tumor. Now, researchers say they have identified that target - an enzyme called PPT1 - opening up a new pathway for potential cancer treatments.READ MORE